Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | CTSK | P43235 | 4/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 3/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4815779 | 1.00 | CTSS (0.51) | CTSSCTSKS1PR3CYP3A4CYP2D6 | |
| SCHEMBL1162807 | 1.00 | CTSS (0.51) | CTSSCTSKS1PR3CYP3A4CYP2D6 | |
| SCHEMBL16174131 | 0.89 | CTSS (0.49) | CTSSCTSKS1PR3CYP3A4CYP2D6 | |
| SCHEMBL16171661 | 0.89 | CTSS (0.49) | CTSSCTSKS1PR3CYP3A4CYP2D6 | |
| SCHEMBL4076640 | 0.88 | CTSS (0.45) | CTSSCTSKS1PR3CYP3A4CYP2D6 | |
| SCHEMBL27813793 | 0.87 | CTSS (0.47) | CTSSCTSKS1PR3CYP3A4CYP2D6 | |
| SCHEMBL17723343 | 0.87 | CTSS (0.47) | CTSSCTSKS1PR3CYP3A4CYP2D6 | |
| SCHEMBL8513252 | 0.86 | CTSS (0.52) | CTSSCTSKS1PR3TSHRATM | |
| SCHEMBL843924 | 0.86 | CTSS (0.52) | CTSSCTSKS1PR3ATMPPARA | |
| SCHEMBL191986 | 0.86 | CTSS (0.52) | CTSSCTSKS1PR3ATMPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4721737-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12435181-B2 | Formulations capable of reacting with or removal of molecular oxygen | LI SHENSHEN (US) | 2025-10-07 | — | — | US | disclosed |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| WO-2024245143-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES | 赛诺哈勃药业（成都）有限公司 | 2024-12-05 | — | — | WO | disclosed |
| EP-4455136-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2024-10-30 | — | — | EP | disclosed |
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| CN-118510768-A | Diazasulfinyl structure-containing compounds and their use in medicine | 赛诺哈勃药业（成都）有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-118271397-A | Polysubstituted pyrazole amide compound, preparation method and application thereof | 浙大城市学院 | 2024-07-02 | — | — | CN | disclosed |
| WO-2010039789-A1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20100029686-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009153180-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
| WO-2009016087-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036422-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| WO-2008074035-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20070275954-A1 | Novel Fused Heterocycles and Uses Thereof | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | US | disclosed |
| EP-1751119-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | AstraZeneca AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005111001-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | BCL9, USP9X, BCL9L | CTSS 3901/4885CTSK 3618/4885S1PR3 2005/4885 |
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | CTSS 431/4885CTSK 249/4885S1PR3 4593/4885 |
| US-20100029686-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | SERPINB1, PEPD, PREP | CTSS 40/4885CTSK 86/4885S1PR3 4646/4885 |
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | CTSS 1741/4885CTSK 3769/4885S1PR3 368/4885 |
| US-20070275954-A1 | Novel Fused Heterocycles and Uses Thereof | VIP, CCKBR, HRH2 | CTSS 973/4885CTSK 837/4885S1PR3 4476/4885 |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC3, HDAC1 | CTSS 97/4885CTSK 322/4885S1PR3 3886/4885 |
| US-20090036422-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, MTNR1A | CTSS 4504/4885CTSK 4783/4885S1PR3 132/4885 |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | CTSS 431/4885CTSK 249/4885S1PR3 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.